How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,896 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Apremilast for treating moderate to severe plaque psoriasis

Apremilast for treating moderate to severe plaque psoriasis Apremilast for treating moder Apremilast for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta419 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Apremilast for treating moderate to severe plaque psoriasis (TA419) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 32Contents Contents 1 Recommendations 4 2 The technology 5 3

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

102. Psoriasis

Psoriasis EDF Guidelines Secretariat to Professor Dr. Nast: Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charite.de European S3-Guideline on the Systemic Treatment of Psoriasis vulgaris Update Apremilast and Secukinumab EDF in cooperation with EADV and IPC Subcommittee Members: Prof. Dr (...) ) Prof. Dr. Annegret Kuhn, Muenster (Germany) Prof. Dr. Andreas Wollenberg, Munich (Germany) Prof. Dr. Marcus Maurer, Berlin (Germany) Prof. Dr. Christos Zouboulis, Dessau (Germany) Prof. Dr. Dieter Metze, Muenster (Germany) Prof. Dr. Dr. Torsten Zuberbier, Berlin (Germany) Prof. Dr. Kai Munte, Rotterdam (Netherlands) Chairman of EDF Guideline Committee: PD Dr. Alexander Nast, Berlin (Germany) Expiry date: 08/2020 European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update

2017 European Dermatology Forum

103. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites (...) therapy for psoriasis 2017. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-36. [17 references] This is the current release of the guideline. This guideline updates

2017 National Guideline Clearinghouse (partial archive)

104. Biologic therapy for psoriasis

Biologic therapy for psoriasis British Association of Dermatologists FULL VERSION Guidelines for biologic therapy for psoriasis Methods, evidence and recommendations April 2017 NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the processes described in Updated guidance for writing a British Association of Dermatologists (...) : Evidence tables clinical studies 227 Appendix F: Forest plots 296 Appendix G: Stakeholders 342 Appendix H: Study selection flow charts 343 Appendix I: GRADE tables 349 Appendix J: Choice of biologic treatment for psoriasis (decision aid) 385 Appendix K: Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV 389 British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 1 Guideline Development Group members Name Role CLINICAL Ms Tracy Bale British

2017 British Association of Dermatologists

105. Biological therapies for psoriasis do not increase serious infection risk

Biological therapies for psoriasis do not increase serious infection risk Biological therapies for psoriasis do not increase serious infection risk Discover Portal Discover Portal Biological therapies for psoriasis do not increase serious infection risk Published on 23 January 2018 doi: People with psoriasis who take an immune-modulating treatment are no more likely to get serious infections than people taking standard therapies. There are fears that these biological therapies raise the risk (...) of serious infections and this has discouraged their use. They are recommended by NICE for moderate to severe psoriasis. Previous studies have reached conflicting conclusions, making it hard to advise on the true risk. This study used a large database of people with psoriasis from the UK and Ireland. It compared serious infection risk of the biological therapies (etanercept, adalimumab or ustekinumab) with non-biological therapies, after accounting for factors such as other illnesses. It found none

2019 NIHR Dissemination Centre

106. Topical steroids better than vitamin D for treating scalp psoriasis

Topical steroids better than vitamin D for treating scalp psoriasis Topical steroids better than vitamin D for treating scalp psoriasis Discover Portal Discover Portal Topical steroids better than vitamin D for treating scalp psoriasis Published on 14 June 2016 doi: Topical steroids applied to the scalp were more effective and safer for treating psoriasis than topical vitamin D alone. Using steroids in combination with vitamin D was statistically better than using a steroid alone (...) , but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59

2019 NIHR Dissemination Centre

107. Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis

Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis '); } else { document.write(' '); } ACE | Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis Search > > Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis - Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis Published on 3 May 2017 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has not recommended (...) ustekinumab to be listed on the Medication Assistance Fund (MAF) for the treatment of chronic plaque psoriasis and psoriatic arthritis. Factors considered to inform the recommendation for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis. The Agency for Care Effectiveness conducted the evaluation in consultation

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

108. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2016 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Final Evidence Report December 2, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 Page ii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table (...) Institute for Clinical and Economic Review, 2016 Page iii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents Disclosure Statement: Dr. Linder owns stock in Amgen, Biogen, and Eli Lily, has contingent value rights in Sanofi Genzyme (related to alemtuzumab for multiple sclerosis); in the past 3 years, Dr. Linder has received grant support from Astellas Pharma on an unrelated topic (overactive bladder) and Clintrex, which

2017 California Technology Assessment Forum

109. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Full Text available with Trip Pro

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement.Data were analyzed from two double-blind, randomized, controlled phase III studies (UNCOVER (...) -2/3) comparing etanercept (ETN), IXE, and placebo (PBO) in patients with moderate-to-severe plaque psoriasis. Long-term analysis included UNCOVER-3 data from week 0 to week 156.At week 12, a clinically meaningful improvement in itch [Itch Numeric Rating Scale (NRS) reduction ≥ 4] was seen in 70.0%, 88.6%, and 90.8% of the IXE-treated patients in the baseline Itch NRS 4-6, 7-8, and 9-10 groups, respectively (all itch severity groups p < 0.001 versus ETN and PBO). Also, 68.9%, 67.1%, and 73.6

2018 Dermatology and therapy Controlled trial quality: uncertain

110. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Full Text available with Trip Pro

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.To describe patients' experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication (...) with physicians, satisfaction with treatment and concerns regarding treatment options.The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively.Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only

2018 Journal of the European Academy of Dermatology and Venereology

111. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin. Full Text available with Trip Pro

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin. Resident T cells are implicated in the maintenance and recurrence of psoriatic lesions. Whether skin that has not yet experienced psoriasis in patients with established disease harbors pathogenic T cells is less investigated.We sought to analyze the composition of resident T cells and T cell-driven tissue responses in skin never affected by psoriasis from patients with mild (...) disease.Never-lesional skin from patients with psoriasis (NLP) was collected from those with mild disease. T-cell profiles were assessed by using confocal imaging and flow cytometry. Tissue responses to T-cell stimulation were measured by using multiplex and NanoString technology.T-cell activation ex vivo triggered psoriasiform and type I interferon tissue responses in NLP psoriasis. Accordingly, keratinocytes from NLP responded to IFN-γ stimulation with myxovirus 1 (MX1) expression and IFN-α release

2018 Journal of Allergy and Clinical Immunology

112. "GENIPSO": a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. (Abstract)

"GENIPSO": a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Genital psoriasis is often under-recognized.To assess the instantaneous prevalence of genital psoriasis and describe its clinical features, association with a particular subtype of psoriasis and its impact on general and sexual quality of life (QoL).GENIPSO is a prospective study conducted by private and hospital (...) -based dermatologists. This study featured the consecutive inclusion of patients consulting for extragenital psoriasis. The clinical features of psoriasis and genital psoriasis were recorded and QoL and sexual health questionnaires were distributed to patients.Overall, 335 of 776 patients (43·2%) included in the study had genital involvement. All were aware that they had genital lesions but only 135 patients (40%) declared that they had been previously examined. Genital lesions were associated

2018 British Journal of Dermatology

113. To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical

2018 Clinical Trials

114. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Our objective was to compare therapeutic response among patients with early-onset psoriasis (EOP) and late-onset psoriasis (LOP) receiving adalimumab, etanercept, infliximab, ustekinumab, or methotrexate in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Patients were grouped by age of onset: EOP (age ≤ 40 years) or LOP (age > 40 years (...) ). Repeated-measures analysis with logistic regression was used to calculate the adjusted odds ratio (AOR; adjusted for baseline characteristics) for achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) or a percentage of body surface area involved with psoriasis < 3% (%BSA < 3) or %BSA < 1 for all patients; similar sensitivity analyses were performed for each treatment group.Of 7511 patients, 5479 (72.9%) had EOP. The LOP group had a higher likelihood of achieving PGA 0/1 after

2018 American journal of clinical dermatology

115. ‘Psoriasis 1’ reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-κB and STAT signaling pathways Full Text available with Trip Pro

‘Psoriasis 1’ reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-κB and STAT signaling pathways 'Psoriasis 1', a Chinese herbal medicine (CHM) formulation, is extensively used to treat psoriasis in China. Although this CHM formulation yields good therapeutic effect, the underlying mechanism of how this works remains unknown. The present study aimed to test the hypothesis that the CHM formulation 'psoriasis 1' inhibits vitamin D receptor (VDR)‑mediated (...) inflammation in psoriasis. To test this, a model of psoriasis was established by stimulating keratinocytes (HaCaT cells) with tumor necrosis factor (TNF)‑α; these cells were subsequently transfected with a lentiviral VDR RNA interference expression vector. The expression levels of 25‑hydroxyvitamin D3 (25HVD3), TNF‑α, interleukin (IL)‑4, IL‑1, IL‑17C, IL‑23 and IL‑6 were measured using ELISA, and the expression levels of VDR, inhibitor of nuclear factor (NF)‑κB (IKK), NF‑κB, signal transducer and activator

2018 Molecular medicine reports

116. Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016) Full Text available with Trip Pro

Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016) Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the general population.To evaluate the epidemiology and clinical characteristics of patients with psoriasis who seek treatment in outpatient dermatology clinics throughout hospitals in Malaysia.Data were obtained from the Malaysian Psoriasis Registry (MPR). All patients (aged 18 (...) and above) who were notified to the registry from July 2017 to December 2017 were included in this study.Among 15,794 patients, Malays were the most common (50.4%), followed by Chinese (21.4%), Indian (17.6%), and others (10.6%). The mean age onset of psoriasis for our study population was 35.14 ± 16.16 years. Male to female ratio was 1.3 : 1. 23.1% of patients had positive family history of psoriasis. The most common clinical presentation was chronic plaque psoriasis (85.1%), followed by guttate

2018 Dermatology research and practice

117. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA Full Text available with Trip Pro

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis (...) assessments.The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87

2018 Psoriasis: Targets and Therapy

118. Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis Full Text available with Trip Pro

Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis 29852915 2018 11 14 1550-9397 14 6 2018 Jun 15 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine J Clin Sleep Med Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis

2018 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

119. Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity Full Text available with Trip Pro

Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity Mutations in keratin proteins have been vastly associated with a wide array of genodermatoses; however, mutations of keratins in psoriasis have not been fully investigated. The main aim of the current research was to identify the mutation in K14, K10, K16, and K17 genes in two stages of psoriasis (...) and tolerated in nature. In these 33 deleterious mutations were immensely found to decrease keratin protein stability. We also found a correlation between keratin and Psoriasis Area and Severity Index score which added that alteration in keratin gene in skin causes severity of psoriasis.We strongly concluded that acanthosis and abnormal terminal differentiation was mainly due to the mutation in epidermal keratins. In turn, disease severity and relapsing of psoriasis are mainly due to the mutation

2018 Human Genomics

120. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study Full Text available with Trip Pro

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis, which are often difficult to treat. The aim of this phase 3, open-label study was to evaluate efficacy and safety of guselkumab, a human interleukin-23 (...) assessment of treatment-emergent adverse events (TEAE) through week 52. At week 16, the proportions of GPP and EP patients achieving treatment success were 77.8% (7/9) and 90.9% (10/11), respectively. Furthermore, guselkumab treatment consistently showed improvement in responses of secondary end-points such as Psoriasis Area and Severity Index, Investigator's Global Assessment, Japanese Dermatological Association severity index and improvement in body surface area involvement. Improvements in quality

2018 The Journal of dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>